Emmaus Life Sciences, Inc., today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2024.
Read MoreEmmaus Life Sciences, Inc., today reported on its financial condition and results of operations as of and for the year quarters ended March 31 and June 30, 2024.
Read MoreEmmaus Life Sciences, Inc., announced that Willis C. Lee has been appointed as Chief Executive Officer.
Read MoreEmmaus Life Sciences, Inc., today announced receiving the coveted "No Action Indicated" classification following a routine inspection by the United States Food and Drug Administration (FDA) of Emmaus' Postmarketing Adverse Drug Experience (PADE) compliance program.
Read MoreEmmaus Life Sciences, Inc., today reported on its financial condition and results of operations as of and for the year ended December 31, 2023.
Read More